Clinical Trial

Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 11, 2024 (before its estimated August 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05675787
Lead Sponsor Peking University People's Hospital
Conditions Atypical Endometrial Hyperplasia, Endometrial Carcinoma Stage I
Enrollment 82 participants
Start Date 2023-01-06
Primary Completion 2025-08-31 (estimated)
Study Completion 2025-10-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-11